INTRODUCTION
TβRI and TβRII are essential components of TGF-β signaling 1 and play an indispensable role in generation of regulatory T cells (Tregs). In mice, selective deletion of TβRI 2 or TβRII 3, 4 in T cells results in severe defect in Treg generation. However, the underlying mechanisms are poorly understood. The expression of TβRs in T cells determines TGF-β signal strength, which has profound effects on T cell responses and differentiation 5, 6 .
Thus, insights into the mechanisms that regulate TβR expression is not only essential for understanding Treg generation, but also important for treatment of autoimmune diseases, transplant rejection, cancer and infection.
PARP-1 is a nuclear enzyme that is conventionally linked to DNA repair [7] [8] [9] . However, PARP-1 has also been shown to function as a transcription factor involved in the transcription of many genes 10, 11 . Inhibition of PARP-1 activity by inhibitors or gene mutation has been shown to lead to both suppression [12] [13] [14] [15] and exacerbation 16 of chronic inflammation and autoimmune disease models. Recently, it was shown that deletion of PARP-1 inhibited NF-κB activation, decreased TNF-α and inducible NO synthesis in macrophages 14, 17 . However, the role of PARP-1 in T cell mediated immune responses remains elusive.
Here we show that PARP-1 regulates the expression of TβRs and thereby controls Treg 
Materials and Methods
Mice. Generation of PARP-1 -/-(sv/129 x C57BL6 background) mice was previously Fig. 1a-b) , cell proliferation ( Supplementary Fig. 1c) , and activation markers CD44, CD45RB, CD62L and CD69 bone marrow ( Fig. 1a-c) . There was no significant increase of total Treg numbers in PARP-1 -/-bone marrow chimers since the number of total splenocytes in PARP-1 -/-bone marrow chimers was lower (data not shown). These data confirm that PARP-1 deficiency confers T cells with an increased capacity to differentiate toward Treg fate in vivo.
Furthermore, we determined whether PARP-1 deficiency affected Treg generation in culture. We induced Foxp3 expression in naïve CD4 + CD25 -T cells by culturing cells with anti-CD3 antibody, antigen presenting cells (APCs), and TGF-β1 18 . There were higher amounts of Foxp3 mRNA (Fig. 1d, Supplementary Fig. 2a ) and protein ( Fig. 1e,   Supplementary Fig. 2b-c (Fig. 1d, Supplementary Fig. 2b ). In addition, PARP-1 -/-T cells converted to Foxp3 expressing cells much faster than PARP-1 +/+ T cells in response to 2ng/ml TGF-β1 (Supplementary Fig. 2c) . A similar increase in Tregs was (Fig. 2a, Supplementary Fig.   3 ). Fig. 2f-h) . Together these data demonstrate that a deficiency in PARP-1 led to increased expression of TβRI and TβRII in CD4 + T cells, suggesting that PARP-1 may have an inhibitory role in the control of TβR expression.
PARP-1 binds to TβRII but not to TβRI gene
We next determined how PARP-1 regulated TβR expression. We first determined whether Fig. 4a ). We observed binding of PARP-1 to the regions close to the TSS and +1 kb from the TSS at the TβRII gene (Fig. 2i, Supplementary Fig. 4b ).
However we did not detect enrichment of PARP-1 binding to the same regions of the TβRI gene. The data suggest that PARP-1 differentially regulates TβRI and TβRII expression; directly interacting with the promoter of the former, but not the latter.
To further confirm the hypothesis that PARP-1 proteins control TβR gene expression, we overexpressed PARP-1 protein and co-transfected it with pGL4-based constructs which contained a fragment of murine TβR promoter to EL4/LAF cell lines. We found that overexpression of PARP-1 protein reduced the activity of both TβRI and II in the presence of TGF-β1 ( Supplementary Fig. 5 ).These data together further support our hypothesis that PARP-1 negatively regulates TβR signaling.
Inhibition of PARP-1 enzymatic activity increases TβRI but not TβRII expression
We next investigated the mechanisms by which PARP-1 regulated TβRI expression. Since PARP-1 possesses enzymatic activity in addition to its transcriptional function, we determined whether PARP-1 could influence TβRI expression through its catalytic function. We pre-treated wild-type (C57BL/6) CD4 +
CD25
-T cells with PARP-1-specific inhibitor 5-aminoisoquinoline (5-AIQ) 24 , followed by stimulation of these T cells with anti-CD3 and CD28 antibodies for 30 minutes. 5-AIQ treatment can significantly upregulate TβRI expression in wild-type CD4 + CD25 -T cells (Fig. 2j) . Surprisingly, 5-AIQ treated CD4 + CD25 -T cells showed no significant changes in TβRII expression compared
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PARP-1 deletion leads to increased Smad2/3 phosphorylation
As PARP-1 -/-CD4 + T cells showed increased TβR expression, and therefore an increased sensitivity to TGF-β signaling, we next determined the effect of PARP-1-deficiency on the phosphorylation and function of Smad2/3 (Smad2 and/or Smad3). Smad2/3 is immediate downstream mediators of TβRs and key factors in mediating TGF-β-induced
Foxp3 gene transcription 2, 25-27 . We used an anti-phosphorylated Smad2 (P-Smad2) as an indicator for Smad2/3 phosphorylation, 28 and observed that even freshly isolated PARP-
-T cells showed substantially higher amounts of P-Smad2 than PARP- Fig. 3a-b) . This corresponded to the higher levels of TβRs in PARP-1 -/-T cells (Fig. 2a) . Stimulation of PARP-1 -/-CD4 + CD25 -T cells with anti-CD3
and CD28 antibodies for 20-30 minutes substantially enhanced P-Smad2 compared to that of PARP-1 +/+ CD4 + CD25 -T cells (Fig. 3a-b) . As expected, addition of exogenous TGF-β1 increased P-Smad2 in both PARP-1 -/-and PARP-1 +/+ CD4 + T cells compared to stimulation with TCR alone, but the level of P-Smad2 in PARP-1 -/-T cells was still higher than that in PARP-1 +/+ T cells (Fig. 3a-b) . Total Smad2 levels were similar between the PARP-1 -/-and PARP-1 +/+ CD4 + T cells irrespective of treatment (Fig. 3a-b) .
These data suggest PARP-1 regulates Smad2/3 phosphorylation, which is likely due to increased expression of TβR.
PARP-1 regulates Smad3 binding to the Foxp3 transcriptional enhancer
Smad3 has been shown to preferentially binds to the enhancer region of (Fig. 3c) .
More Th17 cells in PARP-1 -/-T cells in response to TGF-β1 and IL-6 in vitro
Since TGF-β1 is also required for Th17 cell differentiation in the presence of proinflammatory cytokine IL-6 6, 30-32 , we next examined whether deletion of PARP-1 affected Th17 cell differentiation. We found that treatment with TGF-β1 and IL-6 in the Fig. 6c ).
Increased expression of Foxp3 and TβRI in human CD4 + T cells following PARP-1 inhibition
Finally, to determine whether the pathways we identified in mouse are present in humans,
we assessed whether reduction of PARP-1 activity in human CD4 + T cells affected Foxp3
For (Fig. 5a) , suggesting PARP-1 controls the sensitivity of human T cells to TGF-β signaling.
We next investigated whether inhibition of PARP-1 activity affected the expression of (Fig. 5b) , which confirmed our results from mice (Fig. 2j) . In contrast to TβRII expression in mouse T cells, inhibition of PARP-1 with 5-AIQ in TCR-stimulated human CD4 + CD25 -T cells resulted in higher levels of TβRII expression compared to control T cells receiving TCR stimulation alone (Fig. 5b) . Nevertheless, the data indicate that PARP-1 also controls the expression of TβRs in human T cells, and therefore could also potentially influence Foxp3 expression in human T cells.
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